Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer

OBJECTIVE: To determine the safety and clinical efficacy of two anti-angiogenic agents, bevacizumab and lenalidomide, with docetaxel and prednisone. PATIENTS AND METHODS: Eligible patients with metastatic castration-resistant prostate cancer enrolled in this open-label, phase II study of lenalidomid...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BJU Int
Main Authors: Madan, Ravi A., Karzai, Fatima H., Ning, Yang-Min, Adesunloye, Bamidele A., Huang, Xuan, Harold, Nancy, Couvillon, Anna, Chun, Guinevere, Cordes, Lisa, Sissung, Tristan, Beedie, Shaunna L., Dawson, Nancy A., Theoret, Marc R., McLeod, David G., Rosner, Inger, Trepel, Jane B., Lee, Min-Jung, Tomita, Yusuke, Lee, Sunmin, Chen, Clara, Steinberg, Seth M., Arlen, Philip M., Gulley, James L., Figg, William D., Dahut, William L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6387685/
https://ncbi.nlm.nih.gov/pubmed/26780387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bju.13412
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados